文献速递冠心病外科

血液透析动静脉瘘对冠状动脉旁路移植临床结局的影响

Impact of Arteriovenous Fistula for Hemodialysis on Clinical Outcomes of Coronary Artery Bypass.
PubMed 文献 · Ann Thorac Surg · 2018-08-14

本研究比较了上肢动静脉瘘患者行冠状动脉旁路移植时,原位与游离内乳动脉桥的临床结局。共纳入85例透析依赖患者,原位组48例(56%),游离组37例(44%),随访32.0±38.1个月。两组院内死亡、全因死亡及无主要不良心脏事件生存无显著差异,但原位组心脏相关死亡仅见5例,且同侧原位桥与透析诱发胸痛相关(OR 5.528,95%CI 1.079-28.333,P=0.040)。

要点

  • 原位内乳动脉桥与透析诱发胸痛相关(OR 5.528,95%CI 1.079-28.333,P=0.040)。
  • 原位非复合、原位复合与游离桥的透析诱发胸痛发生率分别为45.5%、19.4%和5.7%(P=0.009)。
  • 两组院内死亡、全因死亡及无主要不良心脏事件生存无显著差异。

核心结论

  • 在上肢动静脉瘘患者中,使用同侧原位内乳动脉桥不影响死亡率,但可能增加透析诱发胸痛的发生率,作者认为游离内乳动脉桥可作为替代选择。

研究设计与样本

  • 回顾性队列研究,纳入85例透析依赖且存在上肢动静脉瘘、使用内乳动脉桥行冠状动脉旁路移植的患者,分为原位组48例(56%)和游离组37例(44%),随访32.0±38.1个月。

主要发现

  • 所有出院患者3年、5年和10年估计总生存率分别为89.5%、81.6%和53%。
  • 两组院内死亡、全因死亡及无主要不良心脏事件生存无显著差异,但心脏相关死亡仅见于原位组(n=5)。
  • 同侧原位桥与透析诱发胸痛相关(OR 5.528,95%CI 1.079-28.333,P=0.040)。
  • 原位非复合桥、原位复合桥和游离桥患者的透析诱发胸痛发生率分别为45.5%、19.4%和5.7%(P=0.009)。

临床怎么用

  • 作者认为,对于存在上肢动静脉瘘的患者,游离内乳动脉桥可作为替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study compared clinical outcomes between the use of in situ and free internal thoracic artery grafts in patients with upper extremity arteriovenous fistula who underwent coronary artery bypass. METHODS: We reviewed 85 hemodialysis-dependent patients with upper extremity arteriovenous fistula who underwent coronary artery bypass with internal thoracic artery grafts. The patients were categorized into 2 groups; 48 (56%) with in situ graft ipsilateral to the arteriovenous fistula (group I) and 37 (44%) with free grafts anastomosed to the ascending aorta (group F). The follow-up period was 32.0 ± 38.1 months. RESULTS: The estimated overall survival rates at 3, 5, and 10 years were 89.5%, 81.6%, and 53%, respectively, for all discharged patients. There was no significant difference in in-hospital mortality, all-cause mortality, and freedom from major adverse cardiac events between the groups, although cardiac-related deaths occurred only in group I (n = 5). Ipsilateral in situ grafts were associated with hemodialysis-induced chest pain (odds ratio, 5.528; 95% confidence interval, 1.079 to 28.333; p = 0.040). The incidence of dialysis-induced chest pain in patients with in situ noncomposite, in situ composite, and free grafts was 45.5%, 19.4%, and 5.7%, respectively (p = 0.009). CONCLUSIONS: Mortality was not influenced by using the internal thoracic artery as an ipsilateral in situ graft in patients with upper extremity arteriovenous fistula. However, there was a risk of increased incidence of hemodialysis-induced chest pain that is most likely related to coronary steal. A free internal thoracic artery graft would be an alternative option in these patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Shim H, Jeong DS, Kim WS, et al. Impact of Arteriovenous Fistula for Hemodialysis on Clinical Outcomes of Coronary Artery Bypass. Ann Thorac Surg. 2018. PMID: 30118708. doi:10.1016/j.athoracsur.2018.06.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。